Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
about
Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: long-term follow-up of a single-centre, phase 2 study
description
scientific article published on 01 December 2018
@en
name
Combination of hyper-CVAD with ...... a single-centre, phase 2 study
@en
type
label
Combination of hyper-CVAD with ...... a single-centre, phase 2 study
@en
prefLabel
Combination of hyper-CVAD with ...... a single-centre, phase 2 study
@en
P2093
P1476
Combination of hyper-CVAD with ...... a single-centre, phase 2 study
@en
P2093
Courtney D DiNardo
Elias Jabbour
Farhad Ravandi
Guillermo Garcia-Manero
Hagop Kantarjian
Jeffrey Jorgensen
Joie Alvarez
Joseph D Khoury
Marina Konopleva
Naval Daver
P304
P356
10.1016/S2352-3026(18)30176-5
P577
2018-12-01T00:00:00Z